Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DSS, Inc. (DSS)

NYSE American - NYSE American Delayed Price. Currency in USD
0.1950+0.0004 (+0.21%)
At close: 03:59PM EST
0.1946 -0.00 (-0.21%)
After hours: 07:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1946
Open0.2000
Bid0.1935 x 1400
Ask0.2115 x 900
Day's Range0.1950 - 0.2017
52 Week Range0.1950 - 0.8200
Volume119,042
Avg. Volume172,304
Market Cap15.55M
Beta (5Y Monthly)1.57
PE Ratio (TTM)0.62
EPS (TTM)0.3130
Earnings DateNov 16, 2022 - Nov 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.37
  • Zacks Small Cap Research

    DSS: Q3 Results Were Hurt By Cost Increases for Packaging and Unrealized Losses on Investments

    By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT DSS (NYSE:DSS) reported revenues of $11.9 million, up 160% from a year ago’s $4.6 million. Direct marketing and printed products both contributed 42% of revenues at $$5.0 million and $4.9 million respectively. However, printed product sales were up 47% and up 24% sequentially while direct marketing was up 411% year over year, but down

  • GlobeNewswire

    Impact BioMedical Scientific Partner GRDG Sciences to be Featured in New Documentary

    Impact BioMedical is a wholly owned subsidiary of DSS “A Real-Life Mission Impossible” — Global Research and Discovery Group steps in the spotlight for documentary, “The BioQuest” — Filming to start December 3 ROCHESTER, N.Y., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of peo

  • Zacks Small Cap Research

    DSS: DSS Plans Three Spin Offs in the Next Nine Months, With the First Potentially Worth $160 Million

    By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT Shareholders can look forward to three potential spin-offs at DSS (NYSE:DSS) in the next nine months. Investors are aware of the imminent spin-off of Impact Biomedical, as its red herring has been filed, and it is in the comments phase with the SEC. However, a spin-off of American Pacific Bancorp could actually happen more quickly as it

Advertisement
Advertisement